---
title: "Insider Selling: Kura Oncology (NASDAQ:KURA) Insider Sells 6,414 Shares of Stock"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/273994812.md"
description: "Kura Oncology insider Brian Powl sold 6,414 shares at $8.46 each, totaling $54,262.44, reducing his ownership by 3.38%. Post-sale, he holds 183,275 shares valued at approximately $1.55 million. The sale was disclosed to the SEC. Kura's stock opened at $8.47, with a market cap of $737.06 million and a negative P/E ratio of -3.42. Recent insider sales have raised concerns, impacting market sentiment, despite some institutional investors increasing their positions. Analysts have mixed ratings, with a consensus target price around $28."
datetime: "2026-01-28T13:12:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/273994812.md)
  - [en](https://longbridge.com/en/news/273994812.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/273994812.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/273994812.md) | [繁體中文](https://longbridge.com/zh-HK/news/273994812.md)


# Insider Selling: Kura Oncology (NASDAQ:KURA) Insider Sells 6,414 Shares of Stock

Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) insider Brian Powl sold 6,414 shares of the company's stock in a transaction dated Tuesday, January 27th. The stock was sold at an average price of $8.46, for a total value of $54,262.44. Following the completion of the transaction, the insider directly owned 183,275 shares of the company's stock, valued at approximately $1,550,506.50. The trade was a 3.38% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Get **Kura Oncology** alerts:

## Kura Oncology Trading Down 1.2%

-   Is Kintara Therapeutics A Hidden Gem?

KURA opened at $8.47 on Wednesday. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.12 and a quick ratio of 5.12. Kura Oncology, Inc. has a fifty-two week low of $5.41 and a fifty-two week high of $12.49. The company's 50 day moving average price is $10.33 and its two-hundred day moving average price is $9.05. The firm has a market capitalization of $737.06 million, a price-to-earnings ratio of -3.42 and a beta of 0.25.

Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.28). The business had revenue of $20.75 million during the quarter, compared to the consensus estimate of $17.48 million. Kura Oncology had a negative return on equity of 65.42% and a negative net margin of 208.48%. As a group, research analysts predict that Kura Oncology, Inc. will post -2.44 earnings per share for the current year.

## Hedge Funds Weigh In On Kura Oncology

Institutional investors have recently made changes to their positions in the stock. EverSource Wealth Advisors LLC increased its position in Kura Oncology by 392.8% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 3,854 shares of the company's stock valued at $34,000 after buying an additional 3,072 shares in the last quarter. PNC Financial Services Group Inc. grew its stake in Kura Oncology by 127.2% in the third quarter. PNC Financial Services Group Inc. now owns 6,732 shares of the company's stock valued at $60,000 after acquiring an additional 3,769 shares during the period. Merit Financial Group LLC bought a new stake in shares of Kura Oncology during the third quarter valued at approximately $89,000. Jain Global LLC acquired a new position in shares of Kura Oncology during the third quarter worth approximately $91,000. Finally, Lazard Asset Management LLC lifted its holdings in shares of Kura Oncology by 222.3% in the 3rd quarter. Lazard Asset Management LLC now owns 10,423 shares of the company's stock worth $92,000 after purchasing an additional 7,189 shares in the last quarter.

## Key Kura Oncology News

Here are the key news stories impacting Kura Oncology this week:

-   Positive Sentiment: Large institutional holders have been increasing positions in KURA (Vanguard, EcoR1 Capital, Jacobs Levy, Geode, Qube Research), signaling continued institutional conviction that could provide support under recent selling. MarketBeat KURA profile
-   Neutral Sentiment: Analyst coverage is mixed: several firms maintain buy/outperform ratings with high targets (consensus target ~ $28), while others recently downgraded or reiterated sell views — a split that can sustain volatility but also leaves upside if clinical/news catalysts arrive. Analyst notes
-   Negative Sentiment: Teresa Brophy Bair (insider) sold 11,208 shares at an average $8.46 (proceeds ~$94,820); post-sale holdings 226,931 shares (~4.71% reduction). This large director/officer sale is likely weighing on sentiment. SEC filing
-   Negative Sentiment: Mollie Leoni (insider) sold 8,180 shares at $8.46 (proceeds ~$69,203); post-sale holdings 267,274 shares (~2.97% reduction). SEC filing
-   Negative Sentiment: Thomas James Doyle (SVP) sold 7,142 shares at $8.46 (proceeds ~$60,421); post-sale holdings 145,167 shares (~4.69% reduction). SEC filing
-   Negative Sentiment: Kathleen Ford (COO) sold 1,813 shares at $8.46 (proceeds ~$15,338); post-sale holdings 153,560 shares (~1.17% reduction). SEC filing
-   Negative Sentiment: Francis Burrows (insider) sold 1,311 shares at $8.46 (proceeds ~$11,091); post-sale holdings 32,424 shares (~3.89% reduction). This follows prior Burrows sales in December, suggesting ongoing portfolio trimming rather than a one-off. SEC filing

## Analyst Ratings Changes

A number of research firms have weighed in on KURA. JMP Securities reissued a "market outperform" rating and set a $24.00 target price on shares of Kura Oncology in a research report on Monday, October 20th. Barclays reiterated an "overweight" rating and set a $28.00 price objective (up from $11.00) on shares of Kura Oncology in a research report on Monday, November 24th. Zacks Research lowered shares of Kura Oncology from a "hold" rating to a "strong sell" rating in a report on Tuesday, January 20th. UBS Group increased their price target on Kura Oncology from $14.00 to $16.00 and gave the stock a "buy" rating in a report on Friday, November 14th. Finally, Leerink Partners set a $20.00 price objective on Kura Oncology and gave the stock an "outperform" rating in a research report on Tuesday, January 13th. Nine investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $28.00.

**View Our Latest Research Report on Kura Oncology**

## Kura Oncology Company Profile

(Get Free Report)

Kura Oncology, Inc NASDAQ: KURA is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura's research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company's lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.

## See Also

-   Five stocks we like better than Kura Oncology
-   America's Next Power Move Starts Underground
-   Your Signature Is Missing – Act Before It’s Too Late
-   NEW LAW: Congress Approves Setup For Digital Dollar?
-   Refund From 1933: Trump’s Reset May Create Instant Wealth
-   BSEM: A $25.50 Price Target, and Nasdaq on the Horizon!

_This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._

## Should You Invest $1,000 in Kura Oncology Right Now?

Before you consider Kura Oncology, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kura Oncology wasn't on the list.

While Kura Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

### 相关股票

- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-CN/quote/SBIO.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-CN/quote/PBE.US.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-CN/quote/FBT.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-CN/quote/IBB.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-CN/quote/IBBQ.US.md)
- [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-CN/quote/ARKG.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-CN/quote/BBH.US.md)
- [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-CN/quote/BIB.US.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-CN/quote/XBI.US.md)
- [Kura Oncology (KURA.US)](https://longbridge.com/zh-CN/quote/KURA.US.md)

## 相关资讯与研究

- [Early Komzifti Traction and Clinical Catalysts Underpin Buy Rating and 2028 Growth Outlook](https://longbridge.com/zh-CN/news/277979016.md)
- [Citius Oncology Reports Positive Phase 1 LYMPHIR Combination Data](https://longbridge.com/zh-CN/news/278565911.md)
- [C-Further Unveils First Therapeutic Programmes Dedicated to Paediatric Oncology | INKT Stock News](https://longbridge.com/zh-CN/news/278521475.md)
- [Vertex's kidney disease drug meets main goal in late-stage trial](https://longbridge.com/zh-CN/news/278442392.md)
- [Citius Highlights Positive LYMPHIR Phase 1 Gynecologic Cancer Data](https://longbridge.com/zh-CN/news/278566951.md)